Clinical-stage biotechnology company Lipella Pharmaceuticals Inc (Nasdaq:LIPO) on Tuesday announced the receipt of a US patent for its proprietary liposomal drug delivery platform.
The new patent covers key innovations in the company's technology for delivering therapeutic agents via liposome-based vehicles.
This breakthrough technology enables precise, targeted delivery, improving the safety and efficacy of treatments across various therapeutic areas, including oncology, cancer survivorship and immunotherapy. The patent extends market exclusivity for Lipella's lead clinical assets, LP-10 and LP-310, which are currently in Phase 2 trials.
LP-10 is a liposomal formulation of tacrolimus designed to treat haemorrhagic cystitis, while LP-310 is an oral rinse formulation for treating oral lichen planus. Both assets have shown promising results in clinical trials and offer potential solutions for these unmet medical needs.
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Frost & Sullivan honours Novotech
Turnstone Biologics announces strategic restructuring
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Novo Holdings launches Booster Therapeutics
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
KeyBioscience extends Eli Lilly collaboration
Tempest to advance amezalpat combination into pivotal trial for HCC
Pharming initiates Phase II clinical trial for leniolisib in PIDs
NeuroSense Therapeutics pursues early commercialisation of ALS treatment in Canada
Biogen receives FDA Breakthrough Therapy Designation for felzartamab